Nutcracker and Elegen Launch Pilot Program for Faster, Scalable RNA Cancer Therapy Manufacturing

Nutcracker and Elegen’s Pilot Program

Announcement

The nutcracker therapeutics a RNA design and manufacturer and Elegen, a DNA manufacturer are introducing a pilot program to describe the company’s first ever full synthetic, cell-free manufacturing platform for RNA-powered personalized cancer therapeutics (PCTs). This program symbolizes an initiative of bringing access to PCTs also in scalable and timely manner.

PCT

Currently, the PCT clinical trials progress and efforts of therapy developers towards introducing advanced PCTs, reliability, scaling, cost, and speed of traditional production methods are a main challenge. The first step of DNA template production is delayed due to the use of bacterial cells in the process, which can be trustworthy and address contamination that must be eliminated. The second stage of GMP-grade RNA production from the template is an unreliable, inefficient, and slow process that can only discover one therapy per GMP suite, for which a new manufacturing strategy is required.

NMU-Symphony™, a nutcracker therapeutic system, is a secondly owned generation of its nutcracker manufacturing unit that provides low-cost, scalable, and fastest GMP RNA manufacturing access. The potential and capabilities of this system (platform) can provide clinical-grade PCTs consistent within three weeks in the timeframe of RNA sequencing design to introduce a nanoparticle-formulated drug product. The product holds the ability to release earlier than the traditional timeframe. By supporting Elegen’s cell-free GMP-ready DNA template production, the compilation of the two platforms will provide quicker and scalable synthesis of critical, longer neoantigen sequences and eliminate the risk of endotoxin contamination and bioburden.

ENFINIA DNA

ENFINIA DNA, an Elegen’s cell-free discovery, is an unparalleled merge of complexity, length, speed, and accuracy that compiles easily with Nutcracker Therapeutics' current RNA-powered PCT development process. The process accelerates machine learning and artificial intelligence technologies via its Codoncracker™ RNA design software, Processvision™, and the NMU-symphony™ microfluidics biochip-based system technology for better quality monitoring and performance. Together, nutcracker and elegen therapeutic’s technologies will deliver flexible, GMP-ready, and efficient production of individualized nanoparticle-formulated RNA therapeutics.

Views and Statements

Founder and CEO of Elegen, Matthew Hill, said, “With the integration of cell-free DNA with cell-free biochip-based RNA production, the partners and researchers globally will have access to an advanced platform, further helping them in testing and advancing new therapies.”

Co-founder and Chief Technology Officer of Nutcracker Therapeutics, Benjamin Eldridge, said, “Along with the improvement in manufacturing process, we are adding the foundation to democratize PCTs with solutions. The vision achievement is providing developers the ability the produce clinical-grade RNA without any investment in infrastructure.”